SCHEMBL18510345

SCHEMBL18510345

CCC(C)(C)C(=O)C(=O)N1CCCC1c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 3/20 0.65
FKBP1A P62942 11/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17881895 0.88 RIPK1 (0.84) RIPK1FKBP1A
SCHEMBL17881977 0.88 RIPK1 (0.84) RIPK1FKBP1A
SCHEMBL19367188 0.87 RIPK1 (0.50) RIPK1FKBP1A
SCHEMBL17881971 0.84 RIPK1 (0.82) RIPK1FKBP1A
SCHEMBL18510351 0.84 FKBP1A (0.52) RIPK1FKBP1A
SCHEMBL28536599 0.83 RIPK1 (0.80) RIPK1FKBP1A
SCHEMBL19367191 0.80 FKBP1A (0.62) FKBP1A
SCHEMBL19367186 0.80 FKBP1A (0.62) FKBP1A
SCHEMBL18510347 0.80 FKBP1A (0.62) FKBP1A
SCHEMBL17881984 0.79 RIPK1 (1.00) RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210100772-A1 METHODS FOR TREATING ALOPECIA AND ACHROMOTRICHIA DAVID WEINSTEIN CONSULTING INC (US) 2021-04-08 US disclosed
US-20200276157-A1 COMPOSITIONS AND METHODS FOR TREATING ALOPECIA DAVID WEINSTEIN CONSULTING INC (US) 2020-09-03 US disclosed
US-20200276158-A1 COMPOSITIONS AND METHODS FOR TREATING ALOPECIA DAVID WEINSTEIN CONSULTING INC (US) 2020-09-03 US disclosed
US-10709686-B2 Methods for treating pulmonary fibrosis DAVID WEINSTEIN CONSULTING, INC. (US) 2020-07-14 US disclosed
US-20190290612-A1 METHODS FOR TREATING PULMONARY FIBROSIS DAVID WEINSTEIN CONSULTING INC (US) 2019-09-26 US disclosed
US-10363240-B2 Compositions and methods for treating alopecia DAVID WEINSTEIN CONSULTING, INC. (US) 2019-07-30 US disclosed
US-20190216777-A1 COMPOSITIONS AND METHODS FOR TREATING ALOPECIA DAVID WEINSTEIN CONSULTING INC (US) 2019-07-18 US disclosed
US-20190216775-A1 COMPOSITIONS AND METHODS FOR TREATING ALOPECIA DAVID WEINSTEIN CONSULTING INC (US) 2019-07-18 US disclosed
US-10285977-B2 Compositions and methods for treating alopecia DAVID WEINSTEIN CONSULTING, INC. (US) 2019-05-14 US disclosed
US-20180140576-A1 METHODS FOR WOUND HEALING AND SCAR PREVENTION DAVID WEINSTEIN CONSULTING INC (US) 2018-05-24 US disclosed
US-20180140577-A1 COMPOSITIONS AND METHODS FOR TREATING ALOPECIA DAVID WEINSTEIN CONSULTING, INC. 2018-05-24 US disclosed
US-20180140577-A1 COMPOSITIONS AND METHODS FOR TREATING ALOPECIA DAVID WEINSTEIN CONSULTING, INC. 2018-05-24 US disclosed
US-20180140576-A1 METHODS FOR WOUND HEALING AND SCAR PREVENTION DAVID WEINSTEIN CONSULTING INC (US) 2018-05-24 US disclosed
WO-2017165119-A1 METHODS FOR WOUND HEALING AND SCAR PREVENTION WEINSTEIN DAVID (US) 2017-09-28 WO disclosed
US-20170266157-A1 METHODS FOR WOUND HEALING AND SCAR PREVENTION DAVID WEINSTEIN CONSULTING, INC. 2017-09-21 US disclosed
US-20170266157-A1 METHODS FOR WOUND HEALING AND SCAR PREVENTION DAVID WEINSTEIN CONSULTING, INC. 2017-09-21 US disclosed
US-20170202805-A1 COMPOSITIONS AND METHODS FOR TREATING ALOPECIA DAVID WEINSTEIN CONSULTING, INC. 2017-07-20 US disclosed
US-20170202805-A1 COMPOSITIONS AND METHODS FOR TREATING ALOPECIA DAVID WEINSTEIN CONSULTING, INC. 2017-07-20 US disclosed
US-20170042859-A1 COMPOSITIONS AND METHODS FOR TREATING ALOPECIA DAVID WEINSTEIN CONSULTING, INC. 2017-02-16 US disclosed
US-20170042859-A1 COMPOSITIONS AND METHODS FOR TREATING ALOPECIA DAVID WEINSTEIN CONSULTING, INC. 2017-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170042859-A1 COMPOSITIONS AND METHODS FOR TREATING ALOPECIA S100A4, FKBP4, FKBP5 RIPK1 2210/4885FKBP1A 5/4885
US-10285977-B2 Compositions and methods for treating alopecia S100A4, FKBP4, FKBP5 RIPK1 2210/4885FKBP1A 5/4885
US-10709686-B2 Methods for treating pulmonary fibrosis FKBP4, FKBP1B, FKBP3 RIPK1 2164/4885FKBP1A 7/4885
US-20170202805-A1 COMPOSITIONS AND METHODS FOR TREATING ALOPECIA S100A4, FKBP4, FKBP5 RIPK1 2210/4885FKBP1A 5/4885
US-20190216777-A1 COMPOSITIONS AND METHODS FOR TREATING ALOPECIA S100A4, FKBP4, FKBP5 RIPK1 2210/4885FKBP1A 5/4885
US-20200276158-A1 COMPOSITIONS AND METHODS FOR TREATING ALOPECIA S100A4, FKBP4, FKBP5 RIPK1 2210/4885FKBP1A 5/4885
US-20190216775-A1 COMPOSITIONS AND METHODS FOR TREATING ALOPECIA S100A4, FKBP4, FKBP5 RIPK1 2210/4885FKBP1A 5/4885
US-20180140577-A1 COMPOSITIONS AND METHODS FOR TREATING ALOPECIA S100A4, FKBP4, FKBP5 RIPK1 2210/4885FKBP1A 5/4885
US-20180140576-A1 METHODS FOR WOUND HEALING AND SCAR PREVENTION FKBP4, S100A4, FKBP14 RIPK1 2439/4885FKBP1A 5/4885
US-20170266157-A1 METHODS FOR WOUND HEALING AND SCAR PREVENTION FKBP4, S100A4, FKBP14 RIPK1 2439/4885FKBP1A 5/4885
US-20200276157-A1 COMPOSITIONS AND METHODS FOR TREATING ALOPECIA S100A4, FKBP4, FKBP5 RIPK1 2210/4885FKBP1A 5/4885
US-20210100772-A1 METHODS FOR TREATING ALOPECIA AND ACHROMOTRICHIA CYP17A1, CYP21A2, MITF RIPK1 3613/4885FKBP1A 46/4885
US-10363240-B2 Compositions and methods for treating alopecia S100A4, FKBP4, FKBP5 RIPK1 2210/4885FKBP1A 5/4885
US-20190290612-A1 METHODS FOR TREATING PULMONARY FIBROSIS FKBP4, FKBP1B, FKBP3 RIPK1 2164/4885FKBP1A 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.